Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1992 1
1993 2
1995 1
1996 1
1998 1
1999 2
2000 3
2001 4
2002 3
2003 1
2004 3
2005 1
2006 9
2007 11
2008 6
2009 2
2010 12
2011 10
2012 10
2013 14
2014 11
2015 17
2016 14
2017 14
2018 19
2019 20
2020 12
2021 11
2022 8
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28288949

195 results

Results by year

Filters applied: . Clear all
Page 1
A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.
Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG 3rd. Mannis GN, et al. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):377-83. doi: 10.1016/j.clml.2015.02.016. Epub 2015 Feb 14. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25776193 Clinical Trial.
Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.
Ansari M, Théoret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, Vachon MF, Champagne MA, Duval M, Krajinovic M, Bittencourt H; Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group. Ansari M, et al. Ther Drug Monit. 2014 Feb;36(1):93-9. doi: 10.1097/FTD.0b013e3182a04fc7. Ther Drug Monit. 2014. PMID: 24061446
Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH, Bredius RG, Ververs TT, Raphael MF, van Kesteren C, Bierings M, Rademaker CM, den Hartigh J, Uiterwaal CS, Zwaveling J, Boelens JJ. Bartelink IH, et al. Biol Blood Marrow Transplant. 2008 Jan;14(1):88-98. doi: 10.1016/j.bbmt.2007.09.015. Biol Blood Marrow Transplant. 2008. PMID: 18158965 Free article. Clinical Trial.
Retrospective study of the digestive tract mucositis derived from myeloablative and non-myeloablative/reduced-intensity conditionings with busulfan in hematopoietic cell transplantation patient.
Eduardo FP, Bezinelli LM, Gobbi M, Rosin FCP, Carvalho DLC, Ferreira MH, da Silva CC, Hamerschlak N, Corrêa L. Eduardo FP, et al. Support Care Cancer. 2019 Mar;27(3):839-848. doi: 10.1007/s00520-018-4362-3. Epub 2018 Aug 14. Support Care Cancer. 2019. PMID: 30109488
Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
Kletzel M, Jacobsohn D, Duerst R. Kletzel M, et al. Biol Blood Marrow Transplant. 2006 Apr;12(4):472-9. doi: 10.1016/j.bbmt.2005.12.028. Biol Blood Marrow Transplant. 2006. PMID: 16545731 Free article. Clinical Trial.
Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.
Kangarloo SB, Naveed F, Ng ES, Chaudhry MA, Wu J, Bahlis NJ, Brown CB, Daly A, Duggan P, Geddes M, Quinlan D, Savoie ML, Shafey M, Stewart DA, Storek J, Yang M, Zacarias N, Yue P, Magliocco AM, Russell JA. Kangarloo SB, et al. Biol Blood Marrow Transplant. 2012 Feb;18(2):295-301. doi: 10.1016/j.bbmt.2011.07.015. Epub 2011 Jul 27. Biol Blood Marrow Transplant. 2012. PMID: 21801704 Free article. Clinical Trial.
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS.
De La Serna J, Sanz J, Bermúdez A, Cabrero M, Serrano D, Vallejo C, Gómez V, Moraleda JM, Perez SG, Caballero MD, Conde E, Lahuerta JJ, Sanz G. De La Serna J, et al. Bone Marrow Transplant. 2016 Jul;51(7):961-6. doi: 10.1038/bmt.2016.42. Epub 2016 Mar 7. Bone Marrow Transplant. 2016. PMID: 26950372 Clinical Trial.
Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
Ishida H, Kato M, Kudo K, Taga T, Tomizawa D, Miyamura T, Goto H, Inagaki J, Koh K, Terui K, Ogawa A, Kawano Y, Inoue M, Sawada A, Kato K, Atsuta Y, Yamashita T, Adachi S. Ishida H, et al. Biol Blood Marrow Transplant. 2015 Dec;21(12):2141-2147. doi: 10.1016/j.bbmt.2015.08.011. Epub 2015 Aug 10. Biol Blood Marrow Transplant. 2015. PMID: 26271192 Free article.
195 results